Cheryl Zigrand | Authors


Molecular Targets in Non-Small Cell Lung Cancer

November 15, 2013

Today, the treatment options for non-small cell lung cancer (NSCLC) in the United States include targeted therapies aimed at angiogenesis (bevacizumab), EGFR mutations (erlotinib and afatinib), and ALK translocations (crizotinib).

Multidisciplinary Perspectives: Molecular Testing in NSCLC

November 15, 2013

Testing for genetic abnormalities is important in NSCLC, both to ensure that as many patients as possible are benefit from approved therapies and to advance understanding of more targets that may be able to lead to future treatments.